The development of super immunodeficient models has greatly advanced xenograft studies, but they are not suited to all study types. To select the model best suited for your specific PDX or cell line study, including immuno-oncology applications, researchers must be fully informed and understand the intricacies of working with highly immunocompromised mouse models.
Dr. Megan MacBride is Director, Product Marketing at Taconic Biosciences. She obtained an AB in chemistry from Princeton University, and a PhD in chemistry from the Pennsylvania State University. Megan joined Taconic in 2006 and has extensive experience in the development and commercialization of animal models across a range of therapeutic areas, from oncology to metabolic disease.